|2.82||+0.2400||+9.30%||Vol 107.72K||1Y Perf 81.69%|
|Dec 6th, 2023 16:00 DELAYED|
|- -||- -%|
|Target Price||12.00||Analyst Rating||Strong Buy 1.00|
|Potential %||325.53||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-/100||Value Ranking||— -|
|Insiders Value % 3/6/12 mo.||-/-/100||Growth Ranking||★★★★★ — -|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/100||Income Ranking||— -|
|Price Range Ratio 52W %||44.54||Earnings Rating||Strong Buy|
|Market Cap||107.03M||Earnings Date||13th Nov 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.14|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||36.64K|
|Avg. Monthly Volume||47.91K|
|Avg. Quarterly Volume||56.71K|
DiaMedica Therapeutics Inc. (NASDAQ: DMAC) stock closed at 2.82 per share at the end of the most recent trading day (a 9.3% change compared to the prior day closing price) with a volume of 107.72K shares and market capitalization of 107.03M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 9 people. DiaMedica Therapeutics Inc. CEO is Rick Pauls.
The one-year performance of DiaMedica Therapeutics Inc. stock is 81.69%, while year-to-date (YTD) performance is 78.47%. DMAC stock has a five-year performance of -9.03%. Its 52-week range is between 1.27 and 4.75, which gives DMAC stock a 52-week price range ratio of 44.54%
DiaMedica Therapeutics Inc. currently has a PE ratio of -3.00, a price-to-book (PB) ratio of 1.09, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -0.12, a ROA of -30.74%, a ROC of -31.87% and a ROE of -32.08%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from DiaMedica Therapeutics Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.14 for the next earnings report. DiaMedica Therapeutics Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for DiaMedica Therapeutics Inc. is Strong Buy (1), with a target price of $12, which is +325.53% compared to the current price. The earnings rating for DiaMedica Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
DiaMedica Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
DiaMedica Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 15.29, ATR14 : 0.22, CCI20 : 94.80, Chaikin Money Flow : -0.05, MACD : 0.06, Money Flow Index : 62.04, ROC : 8.40, RSI : 54.81, STOCH (14,3) : 49.47, STOCH RSI : 0.38, UO : 47.93, Williams %R : -50.53), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of DiaMedica Therapeutics Inc. in the last 12-months were: David J. Wambeke (Buy at a value of $949 203), Dietrich John Pauls (Buy at a value of $49 997), Giuffre Randall Michael (Buy at a value of $254 150), Kellen Scott (Buy at a value of $39 100), Pauls Dietrich John (Buy at a value of $49 997), Pilnik Richard (Buy at a value of $149 999), Pilnik Richard D. (Buy at a value of $149 999), Randall Michael Giuffre (Buy at a value of $366 777), Semba Charles (Buy at a value of $49 997), Semba Charles Pauling (Buy at a value of $49 997), Von Koch Thomas (Buy at a value of $4 999 999), Wambeke David J. (Buy at a value of $150 003)
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.